Patrick Volkert Vink

Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor.

Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment

Provides supportive care product opportunities for post-surgical and cancer patients

Provides software and data platforms for life science researchers, biomarkers and drug developers

Focuses on the development and commercialization of targeted cancer immunotherapy

Operates as a biotechnology company which develops novel drugs

Develops and commercializes small-molecule kinase inhibitor therapeutics for neurological diseases

Develops active immunotherapy cancer vaccines

Develops therapies for the treatment of bacterial infections

Manufactures pharmaceutical products

Engages in discovery and development of anti-cancer drugs

Operates as a holding company that engages in developing and commercializing novel products for surgery, invasive procedures & chemotherapy

Develops pharmaceuticals for patients with rare and orphan diseases

Discovers and develops novel therapeutics for neuromuscular diseases

Manufactures and markets pharmaceutical products

Manufactures pharmaceutical products

Acts as an alternative investment manager

Manufactures and distributes pharmaceutical products for oncology therapies

Operates as a biopharmaceutical company and develops and commercializing treatments for patients with rare & orphan diseases

F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape.